150 related articles for article (PubMed ID: 36722149)
1. Long-term response to sintilimab, bevacizumab and chemotherapy in heavily pretreated microsatellite stable colon cancer.
Cui Z; Wang Q; Deng M; Meng E; Liu S; Niu B; Han Q
Immunotherapy; 2023 Feb; 15(3):127-133. PubMed ID: 36722149
[TBL] [Abstract][Full Text] [Related]
2. Complete remission in a pretreated, microsatellite-stable,
He L; Li H; Wang Y; Li W; Gao L; Xu B; Hu J; He P; Pu W; Sun G; Wang Z; Han Q; Liu B; Chen H
Front Immunol; 2024; 15():1354613. PubMed ID: 38617840
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature.
Zhang Y; Zhang F; Zhao L; Fu X; Shang Y; Gao Q
BMC Gastroenterol; 2021 Oct; 21(1):399. PubMed ID: 34688262
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial.
Gallois C; Emile JF; Kim S; Monterymard C; Gilabert M; Bez J; Lièvre A; Dahan L; Laurent-Puig P; Mineur L; Coriat R; Legoux JL; Hautefeuille V; Phelip JM; Lecomte T; Sokol H; Capron C; Randrian V; Lepage C; Lomenie N; Kurtz C; Taieb J; Tougeron D
Dig Liver Dis; 2021 Oct; 53(10):1254-1259. PubMed ID: 34215534
[TBL] [Abstract][Full Text] [Related]
5. A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer.
Patel MR; Falchook GS; Hamada K; Makris L; Bendell JC
Cancer Med; 2021 Feb; 10(4):1183-1190. PubMed ID: 33544407
[TBL] [Abstract][Full Text] [Related]
6. Durable responses to tislelizumab plus fruquintinib and radiotherapy in refractory microsatellite stable metastatic colorectal cancer: a case report.
Zhao W; Huang Z
Am J Transl Res; 2023; 15(4):2918-2925. PubMed ID: 37193166
[TBL] [Abstract][Full Text] [Related]
7. Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study.
Yang K; Han L; Wu S; Qu X; Li Q; Zhao C; Zhou J; Jin X; Wang Y; Yan D; Cheng Z; Hua Y; Zhang Y; Ge Y; Sun J; Deng W; Zhao L; Zhao Y
Cancer Immunol Immunother; 2022 Jun; 71(6):1443-1451. PubMed ID: 34689233
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
[TBL] [Abstract][Full Text] [Related]
9. Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case report.
Liu Y; Du J; Zhang P; Meng W; Xiao H
Front Oncol; 2023; 13():1051786. PubMed ID: 36969074
[TBL] [Abstract][Full Text] [Related]
10. Metastatic Colorectal Cancer Patient With Microsatellite Stability and BRAF
Fang C; Lin J; Zhang T; Luo J; Nie D; Li M; Hu X; Zheng Y; Huang X; Xiao Z
Front Oncol; 2021; 11():652394. PubMed ID: 33987088
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of sintilimab and fruquintinib combination treatment in the management of microsatellite-stable metastatic colorectal cancer: a case report.
Lin S; Chen W; Chen Z; Liang J; Zhong L; Jiang M
Ann Transl Med; 2022 Mar; 10(6):380. PubMed ID: 35433988
[TBL] [Abstract][Full Text] [Related]
12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
13. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C
BMC Cancer; 2020 Jul; 20(1):683. PubMed ID: 32698790
[TBL] [Abstract][Full Text] [Related]
14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
15. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Antoniotti C; Rossini D; Pietrantonio F; Catteau A; Salvatore L; Lonardi S; Boquet I; Tamberi S; Marmorino F; Moretto R; Ambrosini M; Tamburini E; Tortora G; Passardi A; Bergamo F; Kassambara A; Sbarrato T; Morano F; Ritorto G; Borelli B; Boccaccino A; Conca V; Giordano M; Ugolini C; Fieschi J; Papadopulos A; Massoué C; Aprile G; Antonuzzo L; Gelsomino F; Martinelli E; Pella N; Masi G; Fontanini G; Boni L; Galon J; Cremolini C;
Lancet Oncol; 2022 Jul; 23(7):876-887. PubMed ID: 35636444
[TBL] [Abstract][Full Text] [Related]
16. Metastatic Colorectal Cancer Patient with Microsatellite Stability and Germline BRAC2 Mutation Shows a Complete Response to Olaparib in Combination with a PD-1 Inhibitor and Bevacizumab: A Case Report and Review of the Literature.
Song M; Zeng X; Wu Q; Huang J; Dong J; Shao L; Sun Z; Lin Y; Chen S
Life (Basel); 2023 May; 13(5):. PubMed ID: 37240828
[TBL] [Abstract][Full Text] [Related]
17. PD-1 inhibitor treatment in a penile cancer patient with MMR/MSI status heterogeneity: A case report.
Du Y; Zhang X; Zhang Y; Li W; Hu W; Zong L; Zhao J
Hum Vaccin Immunother; 2022 Nov; 18(6):2121122. PubMed ID: 36162043
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.
Akin Telli T; Bregni G; Vanhooren M; Saude Conde R; Hendlisz A; Sclafani F
Cancer Treat Rev; 2022 Nov; 110():102460. PubMed ID: 36058142
[TBL] [Abstract][Full Text] [Related]
19. [Immune checkpoint inhibitors in the treatment of colorectal cancer: a review of clinical trials].
Gong XL; Zhao L
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):205-213. PubMed ID: 35340169
[TBL] [Abstract][Full Text] [Related]
20. Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR-mutated non-small cell lung cancer patient: A case report.
Zhang Y; Zhao M; Cao S; Zhang X; Du Y
Thorac Cancer; 2020 Sep; 11(9):2717-2722. PubMed ID: 32656988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
